当前位置: X-MOL 学术JAMA › 论文详情
New Malaria Option.
JAMA ( IF 45.540 ) Pub Date : 2020-01-14 , DOI: 10.1001/jama.2019.20669
Bridget Kuehn

A newer antimalaria medication with a simplified dosing regimen may be useful in US patients as prophylaxis or as an antirelapse treatment, according to a review in the Morbidity and Mortality Weekly Report.

The US Food and Drug Administration approved tafenoquine in 2018 as prophylaxis for individuals traveling to malaria-endemic areas and for antirelapse therapy for people infected with the Plasmodium vivax malaria parasite. Previously, only primaquine was available for antirelapse therapy.

Most antimalarial drugs target the blood stage of the parasite. As such, malaria treatments must be given for months after infection to kill some species such as P vivax and Plasmodium ovale that can lie dormant in the liver for months and then emerge, causing a relapse, the authors explained. In 2016, these 2 species caused about 19% of the roughly 1800 imported malaria cases with an identified species of parasite in the United States. Antirelapse therapy is required for P vivax and P ovale infections and for travelers with intense or prolonged exposure to them.

更新日期:2020-01-21

 

全部期刊列表>>
欢迎访问IOP中国网站
自然职场线上招聘会
GIANT
产业、创新与基础设施
自然科研线上培训服务
材料学研究精选
胸腔和胸部成像专题
屿渡论文,编辑服务
何川
苏昭铭
陈刚
姜涛
李闯创
李刚
北大
隐藏1h前已浏览文章
课题组网站
新版X-MOL期刊搜索和高级搜索功能介绍
ACS材料视界
天合科研
x-mol收录
上海纽约大学
陈芬儿
厦门大学
何振宇
史大永
吉林大学
卓春祥
张昊
杨中悦
试剂库存
down
wechat
bug